Inventor · disambiguated record
Mark J. Mulvihill
Also filed as: MULVIHILL MARK · MULVIHILL MARK J · MULVIHILL MARK JOSEPH · TAVARES PAULA A R
35 granted patents·27 pending applications·333 citations·filing 2000–2024
97Inventor score
Files withOSI PHARM INC12HIBERCELL INC8ARNOLD LEE D6OSI PHARMACEUTICALS LLC6REVOLUTION MEDICINES INC6
Top patents by PatentIndex Score
62 records- 0199US7534797B26,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitorsOSI PHARM INC·Filed 2005·Granted May 19, 2009·100 cites·9 claims
- 0295US7700594B2Fused bicyclic mTOR inhibitorsOSI PHARM INC·Filed 2006·Granted Apr 20, 2010·38 cites·6 claims
- 0391US7923555B2Fused bicyclic mTor inhibitorsOSI PHARM INC·Filed 2008·Granted Apr 12, 2011·15 cites·2 claims
- 0489US8314111B2Fused bicyclic motor inhibitorsCHEN XIN·Filed 2011·Granted Nov 20, 2012·12 cites·2 claims
- 0589US7820662B26,6-bicyclic ring substituted heterobicyclic protein kinase inhibitorsOSI PHARM INC·Filed 2008·Granted Oct 26, 2010·12 cites·19 claims
- 0689US7648987B2Bicyclic protein kinase inhibitorsOSI PHARM INC·Filed 2006·Granted Jan 19, 2010·17 cites·8 claims
- 0788US7943767B2Fused bicyclic mTOR inhibitorsOSI PHARM INC·Filed 2009·Granted May 17, 2011·9 cites·14 claims
- 0888US7459554B2Imidazopyrazine tyrosine kinase inhibitorsOSI PHARM INC·Filed 2004·Granted Dec 2, 2008·45 cites·68 claims
- 0987US8796455B2Fused bicyclic mTOR inhibitorsCHEN XIN·Filed 2013·Granted Aug 5, 2014·8 cites·10 claims
- 1087US8101613B26,6-bicyclic ring substituted heterobicyclic protein kinase inhibitorsARNOLD LEE D·Filed 2009·Granted Jan 24, 2012·10 cites·15 claims
- 1185US9951056B2Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune diseaseBEIJING INNOCARE PHARMA TECH CO LTD·Filed 2014·Granted Apr 24, 2018·5 cites·4 claims
- 1285US6376548B1Enhanced propertied pesticidesROHM & HAAS·Filed 2000·Granted Apr 23, 2002·17 cites·22 claims
- 1384US10301297B2Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune diseaseGUANGZHOU INNOCARE PHARMA TECH CO LTD·Filed 2018·Granted May 28, 2019·3 cites·8 claims
- 1482US7741324B2Imidazotriazines as protein kinase inhibitorsOSI PHARM INC·Filed 2005·Granted Jun 22, 2010·6 cites·12 claims
- 1579US8481733B2Substituted imidazopyr- and imidazotri-azinesCREW ANDREW P·Filed 2009·Granted Jul 9, 2013·7 cites·16 claims
- 1678US8653268B26,6-bicyclic ring substituted heterobicyclic protein kinase inhibitorsOSI PHARMACEUTICALS LLC·Filed 2013·Granted Feb 18, 2014·2 cites·1 claims
- 1777US2025206715A1Compounds that participate in cooperative binding and uses thereofREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 1875US8575164B2Combination cancer therapyARNOLD LEE D·Filed 2008·Granted Nov 5, 2013·1 cites·14 claims
- 1975US8178668B22-aminopyridine kinase inhibitorsSTEINIG ARNO G·Filed 2009·Granted May 15, 2012·3 cites·9 claims
- 2075US6258751B1Substituted triazoles imidazoles and pyrazoles as herbicidesROHM & HAAS·Filed 2000·Granted Jul 10, 2001·8 cites·8 claims
- 2175US2024426833A1Methods and reagents for analyzing protein-protein interfacesREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 2273US7566721B2Substituted thienol[2,3-d]pyrimidines as kinase inhibitorsOSI PHARM INC·Filed 2006·Granted Jul 28, 2009·3 cites·11 claims
- 2371US9351974B2Substituted pteridinones for the treatment of cancerOSI PHARMACEUTICALS LLC·Filed 2012·Granted May 31, 2016·2 cites·10 claims
- 2471US2024139185A1Compounds that participate in cooperative binding and uses thereofREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 2570US8592448B2Substituted pyrrolo[2,3-b]-pyridines and -pyrazinesCHEN XIN·Filed 2009·Granted Nov 26, 2013·1 cites·18 claims
- 2670US8378104B27-aminofuropyridine derivativesOSI PHARMACEUTICALS LLC·Filed 2011·Granted Feb 19, 2013·2 cites·24 claims
- 2769US11345695B2Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune diseaseGUANGZHOU INNOCARE PHARMA TECH CO LTD·Filed 2019·Granted May 31, 2022·0 cites·8 claims
- 2867US7662844B2Naphthylene derivatives as cytochrome P450 inhibitorsOSI PHARM INC·Filed 2004·Granted Feb 16, 2010·6 cites·33 claims
- 2963US8445510B2Fused bicyclic kinase inhibitorsMULVIHILL MARK J·Filed 2011·Granted May 21, 2013·1 cites·15 claims
- 3062US2020197391A1Compounds that participate in cooperative binding and uses thereofREVOLUTION MEDICINES INC·Filed 2019·Application pending·0 cites
- 3160US8367826B26,6-bicyclic ring substituted heterobicyclic protein kinase inhibitorsOSI PHARMACEUTICALS LLC·Filed 2011·Granted Feb 5, 2013·0 cites·8 claims
- 3260US2025339426A1Gcn2 modulator for treating cancerHIBERCELL INC·Filed 2023·Application pending·0 cites
- 3360US2008014200A1Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agentsARNOLD LEE D·Filed 2007·Application pending·0 cites
- 3459US2008299113A1Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agentsARNOLD LEE D·Filed 2006·Application pending·0 cites
- 3557US8735405B26,6-bicyclic ring substituted heterobicyclic protein kinase inhibitorsARNOLD LEE D·Filed 2012·Granted May 27, 2014·0 cites·17 claims
- 3657US2011190496A1FUSED BICYCLIC mTOR INHIBITORSOSI PHARM INC·Filed 2011·Application pending·0 cites
- 3755US2021285955A1Methods and reagents for analyzing protein-protein interfacesREVOLUTION MEDICINES INC·Filed 2018·Application pending·0 cites
- 3854US2020199102A1Compounds that participate in cooperative binding and uses thereofREVOLUTION MEDICINES INC·Filed 2018·Application pending·0 cites
- 3953US12473296B2Perk inhibiting compoundsHIBERCELL INC·Filed 2020·Granted Nov 18, 2025·0 cites·28 claims
- 4053US2009181940A1Imidazopyrazine Tyrosine Kinase InhibitorsOSI PHARM INC·Filed 2008·Application pending·0 cites
- 4152US2024150345A1Gcn2 modulating compounds and uses thereofHIBERCELL INC·Filed 2022·Application pending·0 cites
- 4252US2022348584A1Perk inhibiting indolinyl compoundsHIBERCELL INC·Filed 2020·Application pending·0 cites
- 4351US2022356186A1Perk inhibiting pyrrolopyrimidine compoundsHIBERCELL INC·Filed 2020·Application pending·0 cites
- 4451US2024083897A1Gcn2 modulating compounds and uses thereofHIBERCELL INC·Filed 2022·Application pending·0 cites
- 4550US8022206B2Furo[3,2-C]pyridinesOSI PHARMACEUTICALS LLC·Filed 2009·Granted Sep 20, 2011·0 cites·19 claims
- 4649US2019225611A1Substituted spirocyclic inhibitors of autotaxinX RX INC·Filed 2019·Application pending·0 cites
- 4749US2013253197A1Fused bicyclic kinase inhibitorsOSI PHARMACEUTICALS LLC·Filed 2013·Application pending·0 cites
- 4847US12398178B2Collections of peptides, peptide agents, and methods of use thereofPARABILIS MEDICINES INC·Filed 2019·Granted Aug 26, 2025·0 cites·11 claims
- 4947US2022388964A1(aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditionsHIBERCELL INC·Filed 2020·Application pending·0 cites
- 5046US10233182B2Substituted spirocyclic inhibitors of autotaxinX RX INC·Filed 2018·Granted Mar 19, 2019·0 cites·30 claims
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Mark J. Mulvihill files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →